Status:
COMPLETED
European Study of Cerebral Aspergillosis Treated With Isavuconazole
Lead Sponsor:
Imagine Institute
Conditions:
Cerebral Aspergillosis
Invasive Aspergillosis
Eligibility:
All Genders
Brief Summary
Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first ...
Eligibility Criteria
Inclusion
- Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria
- In child or adult
- Treated by isavuconazole at least 7 days
- Diagnosed between March 2017 and June 2020
Exclusion
- Possible cerebral aspergillosis
- isavuconazole treatment for less than 7 days
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT04486885
Start Date
August 1 2021
End Date
March 1 2023
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Necker-Enfants Malades
Paris, France, 75015